The State of Biosimilars in 2023

Although the U.S biosimilars market has fallen short of expectations since its first product approval in 2015, more have poured onto the market after a slow start. Greater price competition could emerge as more biosimilars of each drug begin to launch….

5 steps to evaluate your tax software

Whether your busy season was good or bad, there’s always room for improvement. Evaluate how your department is performing in these five key areas to get started on your technology planning for next year.Request Free!

6 red flags your tax software is holding you back

Many businesses are held back by legacy systems that require time-consuming manual processes, lack advanced automation, and have limited platform flexibility. In today’s fast-paced business environment, companies need tax software that is efficient, ac…